CELEBRACIÓN DEL DIA MUNDIAL DEL ASMA

CELEBRACIÓN DEL DIA MUNDIAL DEL ASMA

Día Mundial del Asma
Share on facebook
Share on twitter
Share on linkedin
Share on telegram
Share on email
Share on whatsapp

El día 3 de mayo es el Día Mundial del Asma, para sumarnos a las actividades científicas que se organizan a colación del mismo, la Sociedad Española de Farmacología os presenta al grupo del Dr. Julio Cortijo que centra su tarea investigadora en el sistema respiratorio y sus patologías.

Presentación del grupo

The research team is formed by   J.  Cortijo  (IP), scientific researcher in charge of projects of research in this field previously carried out in this laboratory (PB86/0428; FIS 87/1376; FIS 88/1850; FAR 90-0680, SAF 93/0132; SAF 96/200; SAF 99/111; SAF2002-4667; SAF 2005-669; SAF2008-03113; SAF2011-26443; SAF2014-55322-P; SAF2017-82913-R, FEDER 1FD97-1143 CDTI, CENIT, TRACE, PROMETEO/2008/045; PROMETEO II/2013/014) y PROMETEO/2017/023) to study new pharmacological agents in experimental in vitro models relevant for chronic lung disease and the following members from the pharmacology laboratory (PL) and the clinical setting (CS). 

Currently  Julio Cortijo is the principal investigator of group 13 of the CIBERES consortium  (Centro de investigación biomedica en red enfermedades respiratorias (ISCiii).

Composición del grupo

R. Guijarro  (PL and CS; university professor, Thoracic surgeon with extensive experience in the selection of patients and obtaining samples of human lung tissue and counselling on patients, collaborating researcher in previous projects with the main researcher. Patient recruitment will take place during the 3 years of the study at the University Hospital General of Valencia, the collaborating researcher and thoracic surgeon will be responsible for identifying patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD), Idiopathic pulmonary fibrosis (IPF)  and pulmonary hypertension (PH). After performing a lung transplant, the pathological lungs are usually discarded, so these valuable samples can be used for a better understanding of the disease. Dr. R. Guijarro will collect the clinical data of the patients, and once the surgery and lung transplant are finished, they will be responsible for the correct maintenance of the sample until it reaches the Departmente Pharmacology. Medical School of Valencia , where it will be processed. Dr. Guijarro, will be responsible, as well as of the extraction of blood and serum samples, collecting the clinical characteristics of lung function and disease progression with the help of IP and  Dr. Javier Milara.

J. Milara CS and PL, previously scientific researcher del Programa Juan Rodés (JR18/00050), Miguel Servet (CP11/00293), Rio Hortega (CM06/00129) having as the researcher responsible for all these contracts the applicant researcher. Associate Professor of the Department of Pharmacology and Full professor accredited by ANECA.  Investigator of group 13 of the CIBERES consortium  (Centro de investigación biomedica en red enfermedades respiratorias (ISCiii).  Scientific researcher in charge of projects of research in this field:  CP11/00293; PI14/01733; PI17/02158; PI20/01363.

GROUP general indicators of quality of scientific production

Sexenies of researchNineteen
Doctoral theses addressed in the last 10 years22 CUM LAUDE
Total bibliographic citations8442
Index h106

Línea/s líneas de investigación del grupo

New pharmacological agents in experimental in vitro models relevant for chronic lung disease

Proyectos relevantes

Julio Cortijo, and Javier Milara have participated in the European project entitled «New PDEI drugs in wounds» (EUROSTAR E!10192) focused on treatment and the pathophysiology of endothelial dysfunction, pulmonary fibrosis and pulmonary hypertension.

Currently the  Julio Cortijo (principal investigator)  and Javier Milara, are part of the CIBERES consortium, group 13. The participation in the EMPATHY1 and EMPATHY2 projects in the PH line of the CIBERES opened the opportunity to collaborate with the leaders of PH in Spain such as the group of Professor Joan Albert Barberá and Victor Peinado of the Clinic Hospital of Barcelona, Professor Francisco Pérez Vizcaíno and Angel Cogolludo of the Complutense University of Madrid, with multiple collaborations in the field of PH (for example Thorax. 2018 Jun;73(6):519-529; PLoS One. 2018 Jan 24;13(1):e0191239). The group of Dr Jesús Ruiz-Cabello (CIC biomaGUNE, San Sebastián), Ernest Sala (Hospital Son Espases, Palma de Mallorca), Dr Diego A. Rodríguez (Hospital del Mar-IMIM, Barcelona) are also potent groups in the field of PH. International collaborations of our group with team leaders such as Prof. Mark Humbert (Cardiovasc Res. 2019 Sep 14. pii: cvz244), and the Cardiovascular Research Center of School of Medicine at Mount Sinai, New York researchers (Mol Ther. 2019 Dec 6. pii: S1525-0016(19)30553-2) have been done and are currently ongoing. Other international groups includes but not limited to Nazzareno Galiè, Gérald Simonneau and Andrew Peacock that have an intensive research on PH.

Julio Cortijo and Javier Milara have participated have participated in research projects with international pharmaceutical industry:

Contract year1  Contract year Responsible Researcher  Duration (months)
1992Evaluación de la actividad antitusígena de varios fármacos (codeína, dememorfano, cloperastina, levodropropizina). Laboratorios MORRITH/SKF/BEECHAM SA.6
1993New selective inhibitors of PDE IV: Relaxation and inhibition of PDE activity from human bronchus. ZAMBON SA (Milán, Italia)12
1995Effects of fenspiride on PDE activity from human bronchus. IRIS-SERVIER (París, Francia).12
1996Effects of N-acetylcysteine and levulose on human neutrophils and human sensitized airways ZAMBON SA (Milan, Italy).9
1998Effects of new selective PDE4 inhibitors on passively sensitized human isolated airways. ZAMBON SpA (Milán, Italia) E11
1998Effects of N-acetylcysteine, taurine and taurine-chloramine on functional responses of human eosinophils in vitro11
1998Activity of N-acetylcysteine on human isolated bronchus exposed to oxidative stress. ZAMBON SpA (Milán, Italia)9
1999N-Acetilcisteine and taurine on lung fibrosis. ZAMBON SpA (Milán, Italia)7
1999N-Acetilcisteine and taurine on an experimental model of allergic asthma in Brown-Norway rats. ZAMBON SpA (Milán, Italia) E12
1999Modulación farmacológica de la inflamación pulmonar. ZAMBON SpA (Milán, Italia). 1FD97-114327
1999Effect of second generation PDE4 inhibitors (Z15370A) on in vivo and in vitro models relevant to asthma and allergic diseases. ZAMBON SpA (Milán, Italia)8
2000Macrolides on neutrophilic lung inflammation (LPS model) ZAMBON SpA (Milán, Italia)12
2000NAC on NF-kB and iNOS in experimental asthma (BN-rats) ZAMBON SpA (Milán, Italia)6
2000NAC on lung fibrosis (catabolism) ZAMBON SpA (Milán, Italia)12
2001Effects of macrolides on an in vivo experimental model of acute lung injury (extension of previous project) ZAMBON GROUP4
2001Effects of macrolides on an in vivo experimental model of asthma. ZAMBON GROUP.6
2001New PDE4 inhibitors in vivo acute lung injury ZAMBON.4
2001New macrolides in vivo acute lung injury ZAMBON.4
2002Addenda al proyecto sobre New PDE4 inh in vivo ZAMBON.1
2002Addenda al proyecto sobre new macrolides in vivo ZAMBON.1
2002Further studies with new PDE4 inhibitors in experimental in vivo models of lung disease. ZAMBON.3
2002Further studies on the effects of new PDE4 inhibitors on an LPS model of acute lung disease (IRT compounds) ZAMBON1
2002Further studies on the effects of new macrolides on in vivo experimental models of acute lung injury ZAMBON 1 becario adscrito al proyecto6
2002Effect of N-acetylcysteine (NAC) on mucin gene expression and other functional outputs of human cultured bronchial epithelial cells ZAMBON.12
2002  Further studies on the effects of NAC in vitro on human neutrophils obtained from healthy nonsmokers and COPD patients ZAMBON.12
2003Effects of  roflumilast, a potent and selective PDE4 inhibitor on various fubctional outputs in in vitro and in vivo models relevant to COPD.   ALTANA  PHARMA AG.12
2004Effects of  roflumilast, a potent and selective PDE4 inhibitor on various fubctional outputs in in vitro and in vivo models relevant to COPD II (ampliación) .   ALTANA  PHARMA AG. .6
2005Effects of new antioxidant compounds on lipopolysacharide-induced acute lung injury, an in vivo animal model relevant to human disease related to xidant stress CHRONOGEN Inc.6
2005Effects of  selective PDE4 inhibitors (e. g. roflumilats) on invitro and invivo models relevant to COPD ot asma.   ALTANA  PHARMA AG.12
2006Shaping the preclinical profile of roflumilats, an investigational PDE$ inhibitor: Advance in vivo and in vitro estudies.   ALTANA  PHARMA AG.6
2006Effects of  CHNG 2957 (10 mg/Kg) , a new antioxidant compounds on lipopolysacharide-induced acute lung injury, an in vivo animal model relevant to human disease related to xidant stress CHRONOGEN Inc.6
2006Effects of new coumpound CHG182, on bleomycin-induced pulmonary damage, an in vivo animal model relevant to human pulmonary fibrosis and COPD. CHRONOGEN Inc.6
2006Shaping the preclinical profile of roflumilats, an investigational PDE$ inhibitor: Advance in vivo and in vitro estudies. ALTANA  PHARMA AG. .6
2006Effects of new coumpound CHG182, on bleomycin-induced pulmonary damage, an in vivo animal model relevant to human pulmonary fibrosis and COPD. CHRONOGEN Inc . (Repeat experiment)6
2007Effects of compound chgn182 new formulation on bleomycininduced pulmonary damage, an in vivo animal model relevant to human pulmonary fibrosis.  CHRONOGEN Inc.6
2007Effects of compound chgn212 on tgfb- induced matrix protein expression in human lung epithelial cell line a549, an in vitro animal model. CHRONOGEN Inc.6
2007Effects of compound chgn212 on tgfb- induced matrix protein expression in human lung epithelial cell line a549, an in vitro animal model. CHRONOGEN Inc.6
2007Drf-chgn182/dose-range finding for chgn182 on bleomycin-inducepulmonary damage, an in vivo animal model relevant to humanpulmonary FIBROSIS AND COPDCHRONOGEN Inc.6
2007Drf2-chgn/dose-range finding for chronogen (chgn) compounds on bleomycin-inducedpulmonary damage, an in vivo animal model relevant to human pulmonary.  CHRONOGEN  Inc. J6
2007Effects of a New Selective PDE4 Inhibitor on Human Isolated Bronchus.   FOREST RESEARCH INSTITUTE (USA).12
2008In vivo and in vitro investigations to characterize pde4 inhibitors and their interaction with pde5 inhibitors. NYCOMED GMBH12
2010“Effects of Roflumilast N-oxide, a PDE4 inhibitor on selected functions of polarized human bronchial epithelial cells in presence or absence of a long acting ß2-agonist (LABA),  a long acting muscarinic antagonist (LAMA), a glucocorticoid, a PDE5 inhibitor or a statin”  NYCOMED SPAIN.12
2010Differential effects of roflumilast N-oxide, a potent and selective phopsphodiesterase 4 inhibitor, compared to corticosteroids on various inflammatory cell function outputs in vitro models relevant to COPD-ROF-PH-01). FOREST RESEARCH INSTITUTE (USA).12
2010Actividad farmacológica de cuatro compuestos con actividad MABA. ALMIRALL.  12
2011Effect of roflumilast N-oxide, a PDE4 inhibitor on selected functional of polrized human bronchial epithelium cells in presence or absence of  LABA, LAMA, a glucocorticoid, a PDE5 inhibitor or a statin. NYCOMED S.A.  12
2011Effect of Roflumilast on TLR signaling: Differentiation from Corticosteroid. FOREST RESEARCH INSTITUTE (USA).12
2014“Effects of PDE4 inhibitors (e.g. Roflumilast N-oxide) on in vitro models related to pulmonary fibrosis and severe COPD. .Laboratorios  NYCOMED TAKEDA. 12
2014Anti-inflammatory effects of a new pde4 (cpd a ) inhibitor compared to roflumilast in the bn rat ova asthma model. Laboratorios  NYCOMED TAKEDA12
2015Cellular effects of Top-N53 and Top-N44, and analogues – an in vitro study. Laboratorios  TOPADUR.6
2015Analysis of the inflammatory effects of pi3k inhibitors on neutrophils from healthy and severe copd patients. LABORATORIOS RHIZEN PHARMACEUTICALS S.A.  . 12
2015Differential effects of a substance with comparators pandpe4b inhibitor, selective pde4b inhibitor, selective pde4d inhibitor, roflumilast n-oxide and corticosteroids on leukocyte/endothelium interactions in an in vitro model relevant to copd. LABORATORIOS GRUNENTHAL GMBH12
2016Effects of NOX4 inhibitors on primary fibroblasts from IPF patients; an in vitro study GLENMARK PHARMACEUTICALS LIMITED CO.6
2017Differential effects of selective PDE4B inhibitor, pan-PDE4 inhibitor and corticosteroids on various keratinocyte inflammatory and remodeling readouts: in vitro studies relevant to psoriasis. LABORATORIOS GRUNENTHAL GMBH.6
2018Concentration-dependent Effects of Vardenafil, Vl-2 and Sl-5 on Relaxation of Phenylephrine (PE) Pre-contracted Rat Aortic Rings (RAR) with Intact Endothelium or Endothelial Dysfunction Secondary to High Glucose. . Laboratorios  TOPADUR. 2

1All contracts were made through the OTRI or the Fundación Universidad-Empresa.

Aportaciones del grupo al campo de investigación en Asma

The group has supervised  73 doctoral theses. PhD candidates have followed very different career paths.

Últimos trabajos publciados

The research team has extensive experience in basic, preclinical and translational research of respiratory diseases, particularly in PHCLD such as  ASTHMA, pulmonary fibrosis and COPD, PAH, as well as in molecular, cellular and the search for new therapeutic targets. The research group has recent relevant publications in the research topic of this project, such as: Mol Ther. 2020 Feb 5; 28 (2): 394-410; Thorax 2020 Feb; 75 (2): 132-142; Cardiovasc Res. 2019 Sep 1 doi: 10.1093 / cvr / cvz244; Thorax 2018 Jun; 73 (6): 519-529; Respir Res. 2018 Feb 6; 19 (1): 24; PLoS One. 2018 Jan 24; 13 (1): e0191239; Eur Respir J. 2016 Jun; 47 (6): 1737-49; PLoS One. 2015 Jul 20; 10 (7): e0133453; Thorax 2013 Oct; 68 (10): 938-48; Thorax 2013 May; 68 (5): 410-20; Eur Respir J. 2013 Jun; 41 (6): 1264-74; among other publications, where the members of the team of this research project  have collaborated.